** Shares of New Jersey-based drug distributor Wellgistics Health WGRX.O rise 9.3% to $2.95 premarket
** Company announces it is collaborating with Protega Pharmaceuticals to increase patient access to Protega's opioid, Roxybond
** Roxybond is indicated for managing severe pain when other treatments are insufficient
** WGRX has fallen 29% since its debut on February 21
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。